Ovid Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ovid Therapeutics, Inc.
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
Top 10 Start-Up Spotlight Stories In 2020: Theradaptive’s ‘Bone Paint,’ BioIntelliSense’s BioButton, Heart Tech, Portable Ultrasound, Digital Health
A look back at Medtech Insight’s 10 most-read Start-Up Spotlight stories in 2020 pointed to diverse interest among our readers focusing on orthopedics, innovations in cardiac surgery, portable ultrasound tech and digital tools for tracking vital signs and monitoring patients at home.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.